drugset / Trial / NCT03524326
Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I study, which tests the safety of different doses of lenvatinib in combination with cetuximab, to see which dose is the safest in people. This study will help find out if lenvatinib and cetuximab is a safe and useful combination for treating patients with HNSCC and cSCC.
Timeline
- Start
- 2018-04-30
- Primary completion
- 2022-10-13
- Completion
- 2022-10-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Subject | Lenvatinib | Small molecule | 4 mg | Oral |
| Subject | Lenvatinib | Small molecule | 10 mg | Oral |
| Subject | Lenvatinib | Small molecule | 14 mg | Oral |
| Subject | Lenvatinib | Small molecule | 20 mg | Oral |
| Subject | Lenvatinib | Small molecule | 24 mg | Oral |